Cantor S B, Hudson D V, Lichtiger B, Rubenstein E B
Department of Medical Specialties, Ambulatory and Supportive Care Oncology Research Program, University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
J Clin Oncol. 1998 Jul;16(7):2364-70. doi: 10.1200/JCO.1998.16.7.2364.
To determine the cost of transfusing 2 units (U) of packed RBCs at a comprehensive cancer center.
We performed a process-flow analysis to identify all costs of transfusing 2 U of allogeneic packed RBCs on an outpatient basis to patients with either (1) solid tumor who did not undergo bone marrow transplantation (BMT), (2) solid tumor who underwent BMT, (3) hematologic malignancy who did not undergo BMT, (4) hematologic malignancy who underwent allogeneic BMT, or (5) hematologic malignancy who underwent autologous BMT. We conducted structured interviews to determine the personnel time used and physical resources necessary at all steps of the transfusion process.
The mean cost of a 2-U transfusion of allogeneic packed RBCs was $548, $565, $569, $569, and $566 for patients with non-BMT solid tumor, BMT solid tumor, non-BMT hematologic malignancy, allogeneic BMT hematologic malignancy, and autologous BMT hematologic malignancy, respectively. Sensitivity analysis showed that total transfusion costs were sensitive to variations in the amount of clinician compensation and overhead costs, but were relatively insensitive to reasonable variations in the direct costs of blood tests and the blood itself, or the probability or extent of transfusion reaction.
The costs of the transfusion of packed RBCs are greater than previously analyzed, particularly in the cancer care setting.
确定在一家综合癌症中心输注2单位浓缩红细胞的成本。
我们进行了流程分析,以确定在门诊为以下患者输注2单位异体浓缩红细胞的所有成本:(1)未接受骨髓移植(BMT)的实体瘤患者;(2)接受BMT的实体瘤患者;(3)未接受BMT的血液系统恶性肿瘤患者;(4)接受异体BMT的血液系统恶性肿瘤患者;(5)接受自体BMT的血液系统恶性肿瘤患者。我们进行了结构化访谈,以确定输血过程各步骤所需的人员时间和物质资源。
对于未接受BMT的实体瘤患者、接受BMT的实体瘤患者、未接受BMT的血液系统恶性肿瘤患者、接受异体BMT的血液系统恶性肿瘤患者和接受自体BMT的血液系统恶性肿瘤患者,2单位异体浓缩红细胞输血的平均成本分别为548美元、565美元、569美元、569美元和566美元。敏感性分析表明,总输血成本对临床医生薪酬和间接费用的变化敏感,但对血液检测和血液本身的直接成本、输血反应的概率或程度的合理变化相对不敏感。
浓缩红细胞输血的成本高于先前分析的结果,尤其是在癌症治疗环境中。